GlassScriptPhysician profile
Frederick Flint Herman
NPI 1811149610
$35,052.00
in general payments reported to CMS, 2019-2025
42 companies · $14K in 2025
The $14K reported for 2025 was more than what 90% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,407 · 2020: $1,263 · 2021: $2,276 · 2022: $9,724 · 2023: $4,428 · 2024: $2,308 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $7,293 · Education: $232 · Consulting Fee: $62.50 · Travel and Lodging: $54.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,740.00 |
| Food and Beverage | $7,292.86 |
| Education | $232.44 |
| Consulting Fee | $62.50 |
| Travel and Lodging | $54.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $10,848.45 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Optinose US, INC. | $9,580.51 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,182.12 | 2019-2025 | Fasenra, Airsupra, Farxiga |
| Regeneron Healthcare Solutions, INC. | $1,977.53 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,494.30 | 2019-2025 | Nucala, Trelegy Ellipta |
| Csl Behring | $1,437.07 | 2019-2024 | Haegarda, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $1,038.54 | 2020-2025 | Cuvitru, Hyqvia, Eohilia |
| Pfizer INC. | $664.82 | 2019-2025 | |
| Genzyme Corporation | $604.40 | 2019-2025 | |
| Octapharma USA, INC. | $532.21 | 2019-2024 | Cutaquig |
| Vertex Pharmaceuticals Incorporated | $500.00 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $482.57 | 2022-2025 | Sotyktu |
| Abbvie INC. | $465.20 | 2020-2024 | |
| Leo Pharma INC. | $428.34 | 2022-2025 | Adbry, Anzupgo |
| Amgen INC. | $225.82 | 2020-2025 | Tezspire, Actimmune |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.